Malta vs Qatar: HIV/AIDS deaths averted by antiretroviral therapy
Malta
37.73 deaths
in 2024
Qatar
28.01 deaths
in 2024
Malta rank
140th
Qatar rank
143rd
HIV/AIDS deaths averted by antiretroviral therapy over time
- Malta
- Qatar
How they compare
Malta currently reports 37.73 deaths against 28.01 deaths in Qatar, a difference of 9.72 deaths.
That makes Malta's figure about 1.3 times Qatar's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Qatar ahead.
Malta ranks 140th and Qatar ranks 143rd of 157 countries.
Malta has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Malta | Qatar | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 7.82 deaths | 0.0451 deaths | 7.78 deaths | Malta |
| 2010s | 21.94 deaths | 4.48 deaths | 17.45 deaths | Malta |
| 2020s | 34.89 deaths | 19.39 deaths | 15.49 deaths | Malta |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Malta or Qatar?
- Malta, at 37.73 deaths against 28.01 deaths in Qatar as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Malta and Qatar?
- 9.72 deaths, with Malta ahead.
- How many years of comparable data are there for Malta and Qatar?
- 35 years are reported by both, from 1990 to 2024.
- How do Malta and Qatar rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Malta ranks 140th and Qatar ranks 143rd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.